On the Current Care Situation and Treatment of Ocular Mucous Membrane Pemphigoid in Germany

Abstract

Background Ocular involvement in mucous membrane pemphigoid (MMP) is relatively rare, with a prevalence of 25 cases per million population, equating to approx. 2,100 patients throughout Germany. Diagnosis can be difficult – especially in cases of isolated ocular involvement – and treatment can be complex and lengthy. Immunosuppressants or immunomodulatory drugs are often used. Due to the complexity of diagnosis and treatment, MMP patients are usually referred to specialized centers. The aim of this project was to evaluate the current care situation of patients with ocular MMP in Germany.

Methods A paper-based survey was designed and sent to all university eye clinics and other specialized centers in Germany in April 2020. The survey asked about the existence of a specialized outpatient service, the total annual number of patients with MMP, the annual number of newly diagnosed patients, any interdisciplinary collaboration for diagnostic or therapeutic purposes, as well as the local and systemic therapy used.

Results Of a total of 44 clinics, 28 (64%) responded, reporting a total average of 27 ± 42 (0 – 200) patients and 3.6 ± 2.2 (0 – 10) new cases per year. This corresponds to a total of 741 patients. Only nine (32%) of the responding clinics offer specialized MMP clinics. 93% of the centers collaborate with the local dermatology department. 79% perform serological and histological diagnostics in-house. About half of the centers (n = 16) apply a standardized treatment regime. Systemic glucocorticoids (66.7%) are most commonly used, followed by mycophenolate mofetil and dapsone (57.1%), rituximab (33.3%), azathioprine and cyclophosphamide (28.6%), as well as methotrexate (19.0%). The least frequently used treatment is intravenous immunoglobulin (14.3%).

Conclusion This survey of German ophthalmology departments obtained data from about one third of the estimated total cohort of all patients with MMP in Germany. These are presumed to be exclusively patients with at least one ocular involvement. The complex care of these patients is usually provided in collaboration with a dermatologist and with the use of systemic anti-inflammatory medication. Currently, an ophthalmological MMP register is being established to better record the epidemiology and care situation of this rare disease in Germany and to improve it in the long term.

Key words

survey - mucous membrane pemphigoid - immunosuppression - register - Germany - therapy

Publication History

Received: 30 September 2021

Accepted: 10 December 2021

Article published online:
24 May 2022

• References/Literatur

• 1 Chan LS, Ahmed AR, Anhalt GJ. et al. The first international consensus on mucous membrane pemphigoid: Definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 2002; 138: 370-379
• 2 Rashid H, Lamberts A, Borradori L. et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. J Eur Acad Dermatol Venereol 2021; 35: 1750-1764
• 3 Schmidt E, Rashid H, Marzano AV. et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. J Eur Acad Dermatol Venereol 2021; 35: 1926-1948
• 4 Hübner F, Recke A, Zillikens D. et al. Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany. J Invest Dermatol 2016; 136: 2495-2498
• 5 Bertram F, Bröcker EB, Zillikens D. et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434-440
• 6 Geerling G, Roth M. [Pseudopemphigoid Induced by Topical Glaucoma Medications]. Klin Monbl Augenheilkd 2019; 236: 762-766
• 7 Dart JK. The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on. Eye (Lond) 2017; 31: 301-332
• 8 Radford CF, Rauz S, Williams GP. et al. Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom. Eye (Lond) 2012; 26: 1199-1208
• 9 Bobba S, Devlin C, di Girolamo N. et al. Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand. Eye (Lond) 2018; 32: 1636-1643
• 10 Radford CF, Rauz S, Williams GP. et al. Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom. Eye (Lond) 2012; 26: 1199-1208
• 11 Langan SM, Smeeth L, Hubbard R. et al. Bullous pemphigoid and pemphigus vulgaris – Incidence and mortality in the UK: Population based cohort study. BMJ 2008; 337: 160-163
• 12 Joo JS, Yun SJ, Lee SC. et al. Incidence of bullous pemphigoid and pemphigus in Korea. Ann Dermatol 2021; 33: 193-195
• 13 Greenberg M, Glick M, Ship JA. Burketʼs Oral Medicine. Eleventh Edition. Hamilton: BC Decker Inc.; 2008
• 14 Thorne JE, Anhalt GJ, Jabs DA. Mucous Membrane Pemphigoid and Pseudopemphigoid. Ophthalmology 2004; 111: 45-52
• 15 Holtsche MM, Zillikens D, Schmidt E. [Mucous membrane pemphigoid]. Hautarzt 2018; 69: 67-83
• 16 Rashid H, Lamberts A, Borradori L. et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology (EADV) – Part I. J Eur Acad Dermatol Venereol 2021; 35: 1750-1764
• 17 Saw VPJ, Dart JKG, Sitaru C. et al. Cicatrising conjunctivitis with anti-basement membrane autoantibodies in ectodermal dysplasia. Br J Ophthalmol 2008; 92: 1403-1410
• 18 Holland EJ, Olsen TW, Ketcham JM. et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993; 12: 413-419
• 19 Suresh L, Calixto LEM, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26: 66-70
• 20 Foster CS. Immunosuppressive Therapy for External Ocular Inflammatory Disease. Ophthalmology 1980; 87: 140-150
• 21 Deutsche Gesellschaft für Rheumatologie e.V.. Informationen zur Therapie. Merkblätter für Ärztinnen und Ärzte sowie Patientinnen und Patienten. Im Internet (Stand: 06.08.2021): https://dgrh.de/Start/Versorgung/Therapieinformationen/Therapieinformationsb%25C3%25B6gen.html
• 22 Le Roux-Villet C, Prost-Squarcioni C, Alexandre M. et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147: 843-849
• 23 Rübsam A, Stefaniak R, Worm M. et al. Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther 2015; 15: 927-933
• 24 Maley A, Warren M, Haberman I. et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74: 835-840
• 25 Hügel R, Lang A, Lhotta K. et al. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement-adjuvant treatment with immunoadsorption and rituximab. J Dtsch Dermatol Ges 2018; 16: 897-900
• 26 Geerling G, Hille K. Zum Stand der Keratoprothesen mit biologischer Haptik – Die Düsseldorf-Offenburger-Erfahrungen mit Osteo-Odonto- und Tibia-Keratoprothese. Klin Monbl Augenheilkd 2017; 234: 763-769
• 27 Schmidt E, Benoit S, Kampik D. et al. Tibial bone keratoprosthesis: reversing blindness in mucous membrane pemphigoid. J Dtsch Dermatol Ges 2017; 15: 1024-1026
• 28 Geerling G, Dart JKG. Management and outcome of cataract surgery in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 2000; 238: 112-118